Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Brietzke, Elisa
Mansur, Rodrigo B.
and
McIntyre, Roger S.
2017.
Impact of inequalities in health care on the mortality risk of individuals with severe mental illnesses.
Revista Brasileira de Psiquiatria,
Vol. 39,
Issue. 3,
p.
193.
Ebert, Bjarke
Miskowiak, Kamilla
Kloster, Morten
Johansen, Jon
Eckholm, Cara
Wærner, Torbjörn
Holme, Mads
and
Bruun, Louise Meldgaard
2017.
An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: the IMPACT study.
BMC Psychiatry,
Vol. 17,
Issue. 1,
Goldberg, Joseph F.
Ng-Mak, Daisy
Siu, Cynthia
Chuang, Chien-Chia
Rajagopalan, Krithika
and
Loebel, Antony
2017.
Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
CNS Spectrums,
Vol. 22,
Issue. 2,
p.
220.
Christensen, Michael Cronquist
and
Munro, Vicki
2018.
Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Current Medical Research and Opinion,
Vol. 34,
Issue. 4,
p.
593.
Fiorillo, Andrea
Carpiniello, Bernardo
De Giorgi, Serafino
La Pia, Silvestro
Maina, Giuseppe
Sampogna, Gaia
Spina, Edoardo
Tortorella, Alfonso
and
Vita, Antonio
2018.
Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review.
Frontiers in Psychiatry,
Vol. 9,
Issue. ,
Heru, Alison M.
2018.
Family Intervention in the Care of a Patient With Nonepileptic Seizures.
American Journal of Psychiatry,
Vol. 175,
Issue. 9,
p.
824.
Oluboka, Oloruntoba J
Katzman, Martin A
Habert, Jeffrey
McIntosh, Diane
MacQueen, Glenda M
Milev, Roumen V
McIntyre, Roger S
and
Blier, Pierre
2018.
Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.
International Journal of Neuropsychopharmacology,
Vol. 21,
Issue. 2,
p.
128.
McIntyre, Roger S.
Anderson, Nicole
Baune, Bernhard T.
Brietzke, Elisa
Burdick, Katherine
Fossati, Phillipe
Gorwood, Philip
Harmer, Catherine
Harrison, John
Harvey, Philip
Mansur, Rodrigo B.
Medalia, Alice
Miskowiak, Kamilla
Ramey, Tanya
Rong, Carola
Rosenblat, Joshua D.
Young, Allan
and
Stahl, Stephen M.
2019.
Expert Consensus on Screening and Assessment of Cognition in Psychiatry.
CNS Spectrums,
Vol. 24,
Issue. 1,
p.
154.
Potměšil, Petr
2019.
What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?.
Therapeutic Advances in Psychopharmacology,
Vol. 9,
Issue. ,
Kramer, Nicole E.
Cosgrove, Victoria E.
Dunlap, Kiley
Subramaniapillai, Mehala
McIntyre, Roger S.
and
Suppes, Trisha
2019.
A clinical model for identifying an inflammatory phenotype in mood disorders.
Journal of Psychiatric Research,
Vol. 113,
Issue. ,
p.
148.
Chokka, Pratap
Bougie, Joanna
Proulx, Jean
Tvistholm, Anders Holmegaard
and
Ettrup, Anders
2019.
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
CNS Spectrums,
Vol. 24,
Issue. 6,
p.
616.
Wang, G.
Wang, C.X.
Tan, K.H.X.
and
Luo, S.
2019.
Cognitive symptoms in depression and clinical outcomes in a 6-month non-interventional, prospective study of antidepressant treatment in China.
European Neuropsychopharmacology,
Vol. 29,
Issue. ,
p.
S60.
Chokka, Pratap
Bougie, Joanna
Rampakakis, Emmanouil
and
Proulx, Jean
2019.
Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
CNS Spectrums,
Vol. 24,
Issue. 3,
p.
338.
Si, T.M.
Wang, L.N.
Tan, K.H.X.
and
Luo, S.
2019.
Associations between cognitive symptoms and functional outcomes in Chinese patients with depression in a 6-month non-interventional, prospective study.
European Neuropsychopharmacology,
Vol. 29,
Issue. ,
p.
S360.
Cao, Bing
Park, Caroline
Subramaniapillai, Mehala
Lee, Yena
Iacobucci, Michelle
Mansur, Rodrigo B.
Zuckerman, Hannah
Phan, Lee
and
McIntyre, Roger S.
2019.
The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
Frontiers in Psychiatry,
Vol. 10,
Issue. ,
Katzman, Martin A
Wang, Xuemei
Wajsbrot, Dalia B
and
Boucher, Matthieu
2020.
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
Journal of Psychopharmacology,
Vol. 34,
Issue. 3,
p.
280.
Krol, Fas Jacob
Hagin, Michal
Vieta, Eduard
Harazi, Rephael
Lotan, Amit
Strous, Rael D.
Lerer, Bernard
and
Popovic, Dina
2020.
Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials?.
European Neuropsychopharmacology,
Vol. 32,
Issue. ,
p.
1.
Christensen, Michael Cronquist
Wong, Chiew Meng Johnny
and
Baune, Bernhard T.
2020.
Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ?.
Frontiers in Psychiatry,
Vol. 11,
Issue. ,
Shin, Cheolmin
Pae, Chi-Un
Kwak, Kyung Phil
Jeon, Sang Won
Jeong, Hyun-Ghang
Kim, Jong-Woo
Lee, Youn Jung
Patkar, Ashwin A.
and
Han, Changsu
2021.
Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder.
Clinical Psychopharmacology and Neuroscience,
Vol. 19,
Issue. 2,
p.
243.
Hossain, Rajib
Al-Khafaji, Khattab
Khan, Rasel Ahmed
Sarkar, Chandan
Islam, Md. Shahazul
Dey, Dipta
Jain, Divya
Faria, Farhana
Akbor, Rukaya
Atolani, Olubunmi
Oliveira, Sónia M. R.
Siyadatpanah, Abolghasem
Pereira, Maria de Lourdes
and
Islam, Muhammad Torequl
2021.
Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAA and GABAB Receptor Interaction Pathway.
Pharmaceuticals,
Vol. 14,
Issue. 8,
p.
721.